FY2024 EPS Estimates for YS Biopharma Co., Ltd. Lowered by Analyst (NASDAQ:YS)

YS Biopharma Co., Ltd. (NASDAQ:YS) – Stock analysts at Diamond Equity reduced their FY2024 earnings per share estimates for shares of YS Biopharma in a research report issued on Monday, April 22nd. Diamond Equity analyst H. Diamond now forecasts that the company will earn ($0.45) per share for the year, down from their prior estimate of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.45) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.

YS Biopharma Price Performance

Shares of NASDAQ:YS opened at $0.80 on Thursday. The company’s fifty day moving average is $0.67 and its two-hundred day moving average is $0.58. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.09. YS Biopharma has a 12-month low of $0.35 and a 12-month high of $1.97.

Institutional Trading of YS Biopharma

An institutional investor recently bought a new position in YS Biopharma stock. Superstring Capital Management LP purchased a new position in YS Biopharma Co., Ltd. (NASDAQ:YS) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 307,920 shares of the company’s stock, valued at approximately $166,000. Superstring Capital Management LP owned about 0.33% of YS Biopharma at the end of the most recent quarter. Institutional investors own 52.64% of the company’s stock.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.